Butyric Acid

Butyric Acid

SCHEMBL4161012

CCCC(=O)O.CN(C)S(=O)(=O)c1cc2c(cc1Cl)[nH]c(=O)c1[nH]ccc12

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.36
GRIN1 Q05586 2/20 0.36
MAPK1 P28482 3/20 0.36
GSTO1 P78417 3/20 0.35
KDM4E B2RXH2 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
BRD4 O60885 1/20 0.33
ATAD2 Q6PL18 1/20 0.33
CECR2 Q9BXF3 1/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
KMT2A Q03164 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 2/20 0.32
POLB P06746 1/20 0.32
RAB9A P51151 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
XBP1 P17861 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL4169377 0.89 KDM4E (0.34) ALDH1A1GRIN1MAPK1KDM4EKEAP1
Butyric Acid SCHEMBL4171746 0.89 PKM (0.37) ALDH1A1GRIN1MAPK1KDM4EL3MBTL1
Butyric Acid SCHEMBL4157908 0.79 KDM4E (0.34) KDM4EBRD4KMT2AMEN1
Butyric Acid SCHEMBL4162510 0.78 PKM (0.37) KDM4EBRD4LMNAMAPT
Butyric Acid SCHEMBL4161192 0.78 ROCK2 (0.33)
Butyric Acid SCHEMBL4171971 0.78 PKM (0.36) ALDH1A1KDM4EL3MBTL1BRD4KEAP1
Butyric Acid SCHEMBL4169890 0.77 KDM4E (0.59) ALDH1A1KDM4EL3MBTL1KEAP1NFE2L2
Propionic Acid SCHEMBL4162945 0.77 KDM4E (0.47) ALDH1A1GRIN1KDM4EBRD4KEAP1
Butyric Acid SCHEMBL4165214 0.76 ALOX5AP (0.36) KMT2AMEN1
Butyric Acid SCHEMBL4163999 0.75 KDM4E (0.47) ALDH1A1KDM4EKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 ALDH1A1 3830/4885GRIN1 529/4885MAPK1 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.